845673-74-7 Usage
Uses
Used in Pharmaceutical Industry:
(5E,7Z,10Z,13Z,16Z,19Z)-4-oxodocosa-5,7,10,13,16,19-hexaenoic acid is used as a pharmaceutical agent for its anti-inflammatory and anti-cancer properties. It modulates several signaling pathways involved in inflammation and immune response, exerting inhibitory effects on the progression of various diseases.
Used in Nutraceutical Industry:
(5E,7Z,10Z,13Z,16Z,19Z)-4-oxodocosa-5,7,10,13,16,19-hexaenoic acid is used as a nutraceutical ingredient for its potential health benefits. It can be incorporated into dietary supplements and functional foods to support the maintenance of cell membrane integrity and function, as well as to provide anti-inflammatory and anti-cancer effects.
Used in Cosmetic Industry:
(5E,7Z,10Z,13Z,16Z,19Z)-4-oxodocosa-5,7,10,13,16,19-hexaenoic acid is used as an active ingredient in cosmetic products for its potential skin health benefits. It can be incorporated into creams, lotions, and serums to support skin hydration, elasticity, and overall health.
Used in Research and Development:
(5E,7Z,10Z,13Z,16Z,19Z)-4-oxodocosa-5,7,10,13,16,19-hexaenoic acid is used as a research compound for studying its biological activities and potential applications in various fields, such as drug discovery, functional food development, and cosmetic formulation.
Check Digit Verification of cas no
The CAS Registry Mumber 845673-74-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,5,6,7 and 3 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 845673-74:
(8*8)+(7*4)+(6*5)+(5*6)+(4*7)+(3*3)+(2*7)+(1*4)=207
207 % 10 = 7
So 845673-74-7 is a valid CAS Registry Number.
845673-74-7Relevant academic research and scientific papers
Itoh, Toshimasa,Murota, Itsuki,Yoshikai, Kazuyoshi,Yamada, Sachiko,Yamamoto, Keiko
, p. 98 - 108 (2006)
To discover novel peroxisome proliferator-activated receptor γ (PPARγ) agonists that could be used as antidiabetic agents, we designed docosahexaenoic acid (DHA) derivatives (2 and 3), which have a hydrophilic substituent at the C(4)-position, based on the crystal structure of the ligand-binding pocket of PPARγ. These compounds were synthesized via iodolactone as a key intermediate. We found that both DHA derivatives (2 and 3) showed PPARγ transactivation higher than, or comparable to, that of pioglitazone, which is a TZD derivative used as an antidiabetic agent. DHA derivatives related to these potent compounds 2 and 3 were also synthesized to study structure-activity relationships. Furthermore, 4-OH DHA 2, which shows strong PPARγ transcriptional activity, was separated as an optically pure form.
